SMMT Key Statistics, Chart & Performance
The current stock price of SMMT is 19.68 USD. In the past month the price increased by 9.7%. In the past year, price increased by 10.25%.
SMMT Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.29 | 388.96B | ||
| AMGN | AMGEN INC | 14.91 | 175.60B | ||
| GILD | GILEAD SCIENCES INC | 14.79 | 150.25B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.72 | 117.69B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.7 | 83.72B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 780.96 | 52.62B | ||
| INSM | INSMED INC | N/A | 37.53B | ||
| NTRA | NATERA INC | N/A | 32.34B | ||
| BIIB | BIOGEN INC | 11.21 | 27.52B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 22.94B | ||
| INCY | INCYTE CORP | 16.65 | 20.98B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.31 | 20.81B |
Related stock screener links
About SMMT
Company Profile
Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The company is headquartered in Miami, Florida and currently employs 159 full-time employees. The company went IPO on 2004-10-14. Its lead development candidate is ivonescimab, a novel, potential first-in-class bispecific antibody intending to combine the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects of an anti-VEGF compound into a single molecule. Ivonescimab is being developed by both Akeso and the Company in multiple Phase III clinical trials. The company is also developing ivonescimab in non-small cell lung cancer and other solid tumor settings. Ivonescimab is approved in China in combination with chemotherapy for patients with EGFR-mutated non-small cell lung cancer whose tumors have progressed following an EGFR-TKI based on the results of the HARMONi-A clinical trial.
Company Info
SUMMIT THERAPEUTICS INC
601 Brickell Key Drive, Suite 1000
Miami FLORIDA 02142 US
CEO: Robert W. Duggan
Employees: 159
Phone: 13052032034
SUMMIT THERAPEUTICS INC / SMMT FAQ
Can you describe the business of SUMMIT THERAPEUTICS INC?
Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The company is headquartered in Miami, Florida and currently employs 159 full-time employees. The company went IPO on 2004-10-14. Its lead development candidate is ivonescimab, a novel, potential first-in-class bispecific antibody intending to combine the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects of an anti-VEGF compound into a single molecule. Ivonescimab is being developed by both Akeso and the Company in multiple Phase III clinical trials. The company is also developing ivonescimab in non-small cell lung cancer and other solid tumor settings. Ivonescimab is approved in China in combination with chemotherapy for patients with EGFR-mutated non-small cell lung cancer whose tumors have progressed following an EGFR-TKI based on the results of the HARMONi-A clinical trial.
Can you provide the latest stock price for SUMMIT THERAPEUTICS INC?
The current stock price of SMMT is 19.68 USD. The price increased by 4.51% in the last trading session.
What is the dividend status of SUMMIT THERAPEUTICS INC?
SMMT does not pay a dividend.
What is the ChartMill rating of SUMMIT THERAPEUTICS INC stock?
SMMT has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
On which exchange is SMMT stock listed?
SMMT stock is listed on the Nasdaq exchange.
Should I buy SMMT stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on SMMT.
Can you provide the upcoming earnings date for SUMMIT THERAPEUTICS INC?
SUMMIT THERAPEUTICS INC (SMMT) will report earnings on 2026-02-23, before the market open.
SMMT Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to SMMT. When comparing the yearly performance of all stocks, SMMT is a bad performer in the overall market: 60.82% of all stocks are doing better.
SMMT Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to SMMT. While SMMT has a great health rating, there are worries on its profitability.
SMMT Financial Highlights
Over the last trailing twelve months SMMT reported a non-GAAP Earnings per Share(EPS) of -0.6. The EPS decreased by -122.22% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -50.81% | ||
| ROE | -56.93% | ||
| Debt/Equity | 0 |
SMMT Forecast & Estimates
23 analysts have analysed SMMT and the average price target is 33.08 USD. This implies a price increase of 68.08% is expected in the next year compared to the current price of 19.68.